Using genomics in medicine
Elective genomic testing: Practice resource of the National Society of Genetic Counselors
Prioritizing the detection of rare pathogenic variants in population screening

Robert C. Green: By sharing their genetic risks, Hemsworth, Jolie are raising awareness of testing
In this Chicago Tribune post, G2P Director Robert Green writes that Hemsworth and Jolie are accelerating awareness and acceptance of a future where we do not wait to respond to the ravages of so many diseases but rather anticipate, predict and prevent them through genomics.
Public willingness to participate in population DNA screening in Australia
The evolving role of medical geneticists in the era of gene therapy: An urgency to prepare

G2P Newsletter November 2022
In this newsletter, we are excited to announce the date and location of the 2023 International Conference on Newborn Sequencing (ICoNS) happening the week of October 2nd-6th in London. Additionally, we highlight the professional accomplishments of our Senior Genetic Counselor/Project Manager Carrie Blout Zawatsky, as well as our team at the Annual National Society of … Continued

Making genomics as diverse as humanity
The lack of diversity in genomic research may be a call to fundamentally change the research enterprise.
Awareness and utilization of genetic testing among Hispanic/Latino adults living in the US: The Hispanic Community Health Study/Study of Latinos
Workforce considerations when building a precision medicine program

Head start: The promise of universal newborn sequencing
The Illumina Genomics Forum is Illumina’s premier global event advancing the positive impact of genomic health. G2P Director Dr. Robert Green spoke alongside Ryan Taft on building the evidence base for offering comprehensive sequencing for every child at birth.

The path to universal newborn sequencing
At the inaugural International Conference on Newborn Sequencing, researchers from eight studies across the world outlined their plans, goals, and results to date for their newborn sequencing initiatives. The BabySeq Project led by Robert Green at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School was the first randomized clinical trial designed to … Continued

From researcher to patient: Knowledge is power
Last year, our former research assistant, Charlene Preys, underwent genetic counseling and testing for hereditary cancer associated with the ATM gene. Upon receiving her ATM status, Charlene’s risk of developing breast cancer jumped from 12 to 40%, and her risk of developing pancreatic cancer increased from <1% to 10%. Patient organizations and support groups were … Continued

Genomic newborn screening studies around the world begin to take baby steps
At the inaugural International Conference on Newborn Sequencing (ICoNS) in Boston last week hosted by Genomes2People and Ariadne Labs, researchers outlined plans from eight studies in the US, the UK, Europe, and Australia.

Blood from a baby at birth can be gene sequenced to prevent diseases
“This week, Dr. Robert Green is hosting a conference in Boston, bringing together researchers and industry representatives from the U.S., U.K., European Union and Australia to set standards and discuss the challenges and opportunities presented by scaling up newborn genetic sequencing.”
A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases
Patient and provider perspectives on polygenic risk scores: Implications for clinical reporting and utilization
Performance of EHR classifiers for patient eligibility in a clinical trial of precision medicine

Revealing the hidden impact of whole-genome sequencing for newborns
“Would you have your baby’s genes sequenced at birth? A groundbreaking trial that used whole-genome sequencing to predict newborns’ future health, is starting to reveal the impact it has had on the whole family, seven years down the line.”

How overturning Roe v. Wade restricts the power of genomics
The overturning of Roe v. Wade and resulting legal barriers are already restricting screening and reproductive options.
Assessing co-occurring mental health conditions in a multidisciplinary Down syndrome clinic and the role of family history

Precision Medicine World Conference: The path to universal newborn sequencing and disease prevention
PMWC, the “Precision Medicine World Conference” is the largest & original annual conference dedicated to precision medicine. At this year’s PMWC, G2P director Dr. Robert C. Green gave a talk on the path to universal newborn sequencing and disease prevention.

Medical research in genomics – Theory meets practice
Through the Achieving Research Equity & Inclusion Conference, Mass General Brigham engages stakeholders from across the country and our communities for a unique opportunity to change how we do research. Click the link below to hear Dr. Robert C. Green talk about medical research in genomics, where theory meets practice.

Will genetics and genomics deliver precision health?
Hear from a panel of experts, including Dr. Robert C. Green, about the challenges and opportunities ahead for genomics and precision health, as well as how researchers, clinicians and other stakeholders are working to make sure that such efforts are inclusive, equitable, accessible and effective.

Full-genome screening for newborn babies is now on the cards
“Doctors in many places want to sequence and screen babies’ entire genomes at birth. In America there are projects to do just that at Boston Children’s Hospital, Columbia University and Rady Children’s Hospital in San Diego. A pioneering group at Harvard, known as BabySeq, has recently received money to expand its small-scale work to include … Continued

University of Chicago Medicine, Pediatrics Grand Rounds: The 2nd Annual William Meadow Bioethics Debate
In this debate hosted by the University of Chicago School of Medicine, Dr. Lainie Ross and Dr. Robert C. Green both respond to the question “should all newborns have their genomes sequenced at birth?”

Baby’s first genome
“Whole-genome sequencing may be the fastest way to diagnose rare complex diseases, but should it be incorporated into healthy newborn screening?” “We are missing the opportunity to address an increasing number of treatable conditions,” says G2P Dr. Robert Green.

Newborn sequencing and prevention of rare diseases: A new challenge
Dr. Robert C. Green presents at the World Medical Innovation Forum on “Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge.”

Unlocking a cosmos of diversity within the profession of genetic counseling
Reaping the full benefits of personalized medicine requires a cadre of genetic counselors as diverse as our patients. We’re working on it.
Association of Pathogenic Variants in Hereditary Cancer Genes with Multiple Diseases

Genomics in Health Implementation Forum newborn sequencing virtual workshop
On April 5th, 2022, initiatives from around the globe will virtually convene for a meeting of the Genomics in Health Implementation Forum (GHIF). This focused workshop aims to share the status of international efforts establishing genomic newborn screening programs and identify areas for engagement with GA4GH Work Streams.

BabySeq newborn screening project aims for increased diversity in second phase
“BabySeq, the next-generation sequencing-based universal screening program for newborns, is gearing up for a second, expanded study. The lead researchers said they want the four-year, $5.1 million grant to help address a lack of diversity in the first cohort.”
Parental attitudes toward standard newborn screening and newborn genomic sequencing: Findings from the BabySeq Study
Population DNA screening for medically actionable disease risks in adults
Development of clinical polygenic risk score assay and report

How genomics researchers can save their participants’ lives
“Genomic researchers who are returning results to participants need to look at how to incorporate sequencing now, not later.”

Their DNA hides a warning, but they don’t want to know what it says
The MGB Biobank returned actionable genetics results to 256 participants, 76.3 percent of whom were unaware that they carried a variant that put them at increased risk. The New York Times reports on this return of results process, outlining that some participants wanted to learn this information and others did not.